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Abstract
Hepatitis E virus (HEV) is classified within the family Hepeviridae, genus Hepevirus. HEV genotype 3 (Gt3) infections are
endemic in pigs in Western Europe and in North and South America and cause zoonotic infections in humans. Several
serological assays to detect HEV antibodies in pigs have been developed, at first mainly based on HEV genotype 1 (Gt1)
antigens. To develop a sensitive HEV Gt3 ELISA, a recombinant baculovirus expression product of HEV Gt3 open reading
frame-2 was produced and coated onto polystyrene ELISA plates. After incubation of porcine sera, bound HEV antibodies were
detected with anti-porcine anti-IgG and anti-IgM conjugates. For primary estimation of sensitivity and specificity of the assay,
sets of sera were used from pigs experimentally infected with HEV Gt3. For further validation of the assay and to set the cutoff
value, a batch of 1100 pig sera was used. All pig sera were tested using the developed HEV Gt3 assay and two other serologic
assays based on HEV Gt1 antigens. Since there is no gold standard available for HEV antibody testing, further validation and
a definite setting of the cutoff of the developed HEV Gt3 assay were performed using a statistical approach based on Bayes’
theorem. The developed and validated HEV antibody assay showed effective detection of HEV-specific antibodies. This assay
can contribute to an improved detection of HEV antibodies and enable more reliable estimates of the prevalence of HEV Gt3 in
swine in different regions.
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Introduction
Hepatitis E virus (HEV) is a small nonenveloped RNA
virus of approximately 7.2 kb, and has been classified
within the family Hepeviridae, genus Hepevirus. Four
mammalian genotypes (Gt1-4) were identified in the
1990s, and avian HEV had been identified before that (1).
More recently, HEVs have also been identified in rats,
rabbits, ferrets, bats, and trout (2). Gt1 and Gt2 are found
exclusively in humans and are responsible for large
waterborne epidemics and sporadic cases in endemic
regions (Asia, India, Africa, and Mexico) (1). Gt1 and Gt2
can be divided further into five (a-e) and two (a and b)
subtypes, respectively. In contrast, Gt3 and Gt4 are
responsible for sporadic cases in humans and are wide-
spread in animals. Especially for HEV Gt3, it is assumed
that zoonotic transmission plays an important role in human
infections (3). Genotypes 3 and 4 seem more variable
and can be divided into 10 (a-j) and 7 (a-g) subgenotypes,
respectively (4).
Despite the considerable genetic variability observed
between genotypes, to date only one serotype has been
identified. HEV Gt3 infections have been reported to be
endemic in pigs in Europe (5) and in North and South
America (6). HEV infections in humans often run a sub-
clinical course but can also cause serious acute hepatitis.
The disease is characterized by a self-limiting jaundice of
varying severity, which is hard to distinguish from hepati-
tis of other viral origin, and is often accompanied by
nonspecific symptoms such as fever, headache, and pain
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in the upper abdomen. In pigs naturally infected with HEV
Gt3, microscopic lesions of hepatitis are observed, but
overt clinical symptoms in pigs have not been reported.
Autochthonous HEV Gt3 and Gt4 infections in humans
may be zoonotic and may originate from swine reser-
voirs. For this reason, it is suggested that the study of
HEV dynamics in pig populations be done in Europe and
the Americas.
For swine serology, several HEV antibody assays have
been developed, mainly based on HEV Gt1 antigens, in
particular open reading frame (ORF)-2 proteins or pep-
tides. HEV Gt3 antibodies have been shown to cross-react
with Gt1 antigens (7), but, given the high variability of
strains, homologous assays may perform better. Since
HEV Gt3 is the predominant genotype in pigs in Europe
and North America, in this study an HEV antibody assay for
pigs was developed based on the HEV Gt3 antigen. Due to
the fact that there is no gold standard available, in-house
developed or commercially available HEV immunoassays
often have not been validated properly. For final validation
and a definite choice for cutoff of the developed HEV Gt3
assay in this study, posterior Bayesian statistical inference
was used.
A total of 1100 serum samples from fattening pigs
were tested using the newly developed HEV Gt3 assay
and two other HEV immunoassays for comparison. Test
results of the three assays were analyzed simultaneously
with a latent class model [see Engel et al. (8) and
references therein]. This statistical model accounts for the
lack of a gold standard, i.e., no assay or combination of
assays was chosen as a reference.
Material and Methods
HEV ELISA development
A recombinant expression product of HEV (ORF-2, Gt3,
Subtype 3a) was produced in a baculovirus expression
system as previously described (9,10). A synthetic gene
encoding 497 amino acids of swine Gt3 HEV ORF-2,
Subtype 3a, was engineered using the amino acid
sequence published in GenBank AY585859 (Geneart,
Germany). The part of the HEV capsid encoded by this
gene includes the motifs needed for self-assembly into
empty virus-like particles when expressed in Sf9 insect
cells. Codon usage and percentage G and C nucleotide
content were optimized for expression in Sf9 Spodoptera
frugiperda insect cells and a Kozak sequence was
introduced upstream of the ATG. The recombinant bacu-
lovirus was obtained using the Bac-to-Bac1 Baculovirus
Expression System (Invitrogen, France) according to the
manufacturer’s instructions. Sf9 insect cells adapted to a
serum-free medium (Invitrogen) were grown at 276C in
SF900 serum-free medium supplemented with penicillin,
streptomycin, and fungizone (Invitrogen). Viral stocks were
prepared on Sf9 cells, after two plaque purifications also on
Sf9 cells.
Protein expression in the culture medium and cell
lysate was analyzed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and Western blotting using
negative and positive sera from swine. Sf9 cells were
infected with the recombinant baculovirus at a multiplicity
of infection of five. The culture medium was harvested 5
days after infection. Cells and debris were removed by
centrifugation at 10,000 g for 30 min. The supernatant
was then centrifuged at 11,000 g for 3 h in a Beckman
SW28 rotor. The resulting pellet was resuspended in 4 mL
PBS and held overnight at 46C. The sample was then
mixed with 0.44 g/mL CsCl and centrifuged at 15,000 g
for 18 h at 46C in a Beckman SW50.1 rotor. Fractions of
0.5 mL were collected from the bottom of each gradient
and fraction densities were determined using an Abbe
refractometer (Bioblock, France) and stored at a concen-
tration of 0.3 mg/mL.
For the test principle, recombinant protein was coated
onto polystyrene ELISA plates. Recombinant protein was
dissolved 1:1500 in coating buffer (see ELISA proce-
dures), and incubated with the test serum and HEV-
specific swine antibodies were detected using anti-
porcine anti-IgG and IgM conjugates. Antibodies present
in the test serum bound to the antigen during the first
incubation, and during the second incubation, the bound
antibodies were detected using anti-swine monoclonal
antibodies against IgM and against the L-chain conju-
gated to the enzyme horseradish peroxidase (HRP, see
ELISA procedures). Bound conjugate was visualized by
adding a substrate chromogen. Wells containing samples
negative for HEV antibodies remained colorless. To
optimize the ELISA, different concentrations of the
purified recombinant protein were tested using a series
of swine sera from an experimental infection. Swine sera
were tested in different dilutions to establish the optimal
dilution for test sera. A primary cutoff of the assay was
established using sera from two cesarean-delivered
colostrum-deprived, specific pathogen-free pigs. For
primary estimation of sensitivity and specificity of the
assay, sets of sera were used from pigs experimentally
infected with HEV Gt3 (10,11).
All experiments in this study involving the use of
animals were approved by the Ethics Committee for
Animal Experiments of Wageningen University, in accor-
dance with legislation of The Netherlands and the
European Union.
HEV ELISA comparison assays
Two different HEV immunoassays were used for
comparison, a commercially available immunoassay and
an HEV immunoassay that was developed in-house. The
commercially available HEV Ab-ELISA kit (Axiom,
Germany) is a double-antigen sandwich ELISA based
on a recombinant Burmese HEV Gt1 capsid protein
derivative covering the carboxy-terminal amino acid
residues 394-606. Due to its test principle, it can detect
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HEV-specific antibodies independently of the host species
and immunoglobulin class. The manufacturer’s instruc-
tions were strictly adhered to in the assay, including the
recommended thresholds for definition of a positive
serum. The in-house developed HEV immunoassay is a
previously standardized in-house ELISA based on a
purified 55-kDa truncated recombinant capsid protein of
the Sar-55 strain of human HEV Gt1 (Gt1 assay). Based
on its test principles, this immunoassay detects HEV-
specific IgG in pig sera. This immunoassay was
performed as described by Martin et al. (12). The
absorbance of each sample was read with an ELISA
plate reader with a 450-nm filter. Test samples with
absorbances equal to or greater than the cutoff value
(0.300) were considered to be positive for anti-HEV IgG.
In all immunoassays, sera of HEV naive and HEV infected
swine were used as negative and positive controls in
each plate.
HEV ELISA validation
For further validation of the assay and to definitely set
its cutoff value, a batch of 1100 pig sera was used. The
sera were obtained at slaughter from pigs from at least
550 pig farms (maximum two pigs per farm) in The
Netherlands. Potential HEV infections in these pigs were
of Gt3. To date, only HEV Gt3 infections have been found
in pigs in The Netherlands. All pig sera were tested using
the developed HEV Gt3 assay and the two comparison
serologic assays based on HEV Gt1 antigens.
Statistical evaluation of diagnostic test accuracy
The pig sera obtained at slaughter were used for a
Bayesian evaluation of the accuracy of the three ELISA
tests. In a Bayesian analysis two sources of information
are combined: prior information about prevalence, test
sensitivity, and test specificity, and new observations,
which in this case were the ELISA test results. The prior
information attaches a probability to each possible value
of a parameter in the model, e.g., an unknown test
sensitivity. Consequently, the prior information takes the
form of a probability distribution for this sensitivity. This
prior distribution is combined with the data into a posterior
distribution, which is an up-to-date summary of all
available information about the sensitivity. The median
of this posterior distribution is presented as an estimate
and the 95% range as a Bayesian confidence interval
(credible interval) for the sensitivity.
The statistical model distinguishes between the test
results and the true antibody status of the sera. Because
the tests are fallible, observed test results and unob-
served true antibody status are not necessarily the same.
The test results of the three ELISA tests were analyzed
with a latent class model, where the true-antibody status
(seropositive or seronegative) represents the latent
classes.
Data were collected in relatively small batches from
different producers. In the statistical model, each batch
has its own true prevalence, i.e., probability for a true
seropositive, and these different prevalences are
assumed to be sampled from a distribution of prevalence
values. The probabilistic behavior of the tests, in relation
to true antibody status, is modeled according to Engel
et al. (8). The model accounts for possible dependence
between tests for true seropositives and true seronega-
tives.
Prior distributions were based on literature and expert
opinion. For assays based on a Gt3 antigen, prior
emphasis was on a slightly higher specificity. For assays
using more isotypes of antibodies in the conjugate, prior
emphasis was on slightly higher sensitivity. The prior
median and 95% ranges for sensitivity and specificity are
shown in Table 1. The prior range for median prevalence
was chosen from 0.5 to 0.9. Further (technical) details
about model and priors may be found in Supplementary
Material.
Because batches of sera from the same producer
tended to be small, often as small as two sera from the
same producer, parameters for prevalence were hard to
identify from the data. In order to obtain more reliable
inference about the sensitivity and specificity of the tests,
it was assumed that dependence between tests, condi-
tional upon true-negative status, was negligible.
For the CVI (Central Veterinary Institute) test, binary
data were generated at three different thresholds
(20,23,25) and three separate analyses were performed,
one for each threshold.
HEV ELISA procedures
For coating onto polystyrene ELISA plates, the optimal
dilution of the recombinant baculoprotein stock (0.3 mg/
mL) was 1:1500 using a coating buffer (0.05 M sodium
carbonate buffer, pH 9.65). In the final procedure, 100 mL
diluted baculoprotein was dispensed to each well of a
polystyrene ELISA plate (Costar 9018, Greiner Bio-one,
Alphen a/d Rijn, The Netherlands). Plates were covered
with adhesive foil (plate sealer) and incubated overnight
at room temperature. Before usage, ELISA plate(s) were
washed three times using tap water supplemented with
Table 1. Prior 95% range and median for sensitivity and
specificity.
Assay Prior range Prior median
Sensitivity
CVI Gt3 assay 0.70-0.90 0.82
Axiom 0.70-0.90 0.82
Gt1 assay 0.60-0.85 0.74
Specificity
CVI Gt3 assay 0.92-0.97 0.95
Axiom 0.88-0.93 0.91
Gt1 assay 0.90-0.95 0.93
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0.05% Tween 80 in an ELISA plate washer. A volume of
100 mL StabilCoat1 (Diarect AG, Freiburg, Germany)
(diluted 1:1 with PBS) was dispensed to all wells and
incubated 30 min at room temperature. After removal of
StabilCoat1, ELISA plates were dried for 3 h at 376C and
stored at 46C until use. In the final test procedure, sera
were diluted 1:5 in serum dilution buffer: 10% bovine
serum albumin+10% Elk+1% Tergitol (dissolved in
PBS) added to low salt buffer (2.5 mL 10% Tween 80 in
500 mL PBS). One hundred microliters of diluted test
serum was dispensed to the wells and, after sealing,
plates were incubated at room temperature for 1 h. After
this first incubation, plates were washed three times using
tap water supplemented with 0.05% Tween 80 in an
ELISA plate washer. Anti-swine IgM HRP-conjugated
monoclonal antibody (CVI 28.4.1.) was diluted 1:2000 and
the anti-swine L-chain HRP-conjugated monoclonal anti-
body (CVI 27.2.1.) was diluted 1:1000 in conjugate buffer
(5% fetal calf serum) in high salt buffer (14.5 g NaCl in
500 mL PBS, 2.5 mL 10% Tween 80). For the second
incubation, 100 mL of the diluted conjugate solution was
dispensed to each well. Plates were covered with a plate
sealer and incubated for 1 h at room temperature. Sub-
sequently, plates were washed three times with tap water
supplemented with 0.05% Tween 80 using an ELISA
plate washer, and 100 mL ready-to-use 3,39,5,59-tetra-
methylbenzidine substrate was dispensed to each well
and incubated for 10 min at room temperature. The
reaction was stopped by adding 100 mL 0.5 M sulfuric
acid to all wells. The color intensity was measured at




As described in Material and Methods, several
protocols were tested to set up an immunoassay based
on HEV Gt3 recombinant antigen. Final performance of
the developed HEV Gt3 immunoassay was assessed
using sera of pigs experimentally infected with HEV Gt3,
in comparison with a commercially available HEV Ab-
ELISA (Axiom). The results showed slight differences in
the kinetics of anti-HEV antibody detection, but serocon-
version of HEV-infected pigs was detected with both
detection methods (Figure 1).
HEV ELISA validation
The average absorbance values for the set of 1100 pig
sera obtained at slaughter and measured using three
different HEV antibody assays are reported in Table 2.
The estimated sensitivity and specificity of each of
the three tests are shown in Table 3, together with a
95% confidence interval (95%CI, credible interval). These
results correspond to a threshold value of 20 for the CVI
Gt3 assay. For threshold values of 23 and 25, similar
values for estimated sensitivity and specificity were found
for the Axiom and Gt1 assays. For a threshold value of 20,
the CVI Gt3 assay showed the highest sensitivity. For
threshold values of 20, 23, and 25, the CVI Gt3 assay
Figure 1. Hepatitis E virus genotype 3 (Gt3) antibody developments in experimentally HEV Gt3-infected pigs measured by HEV Gt3
ELISA CVI and HEV ELISA Axiom. Test procedures of the developed assay are described in Material and Methods.
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showed similar specificities. For the CVI Gt3 immunoas-
say, the best results were obtained for the threshold value
of 20; therefore, this value was chosen to be used as the
primary choice cutoff value for the test.
The higher specificity of the Gt1 assay (0.94,
95%CI=0.92-0.96) was apparently achieved at the cost
of a modest sensitivity (0.58, 95%CI=0.55-0.62). CVI Gt3
and Axiom had a similar specificity (0.89, 95%CI=0.88-
0.90), but the estimated sensitivity of Axiom (0.93,
95%CI=0.90-0.94) was higher than that of CVI Gt3
(0.84, 95%CI=0.81-0.86).
The estimated median prevalence was 0.95
(95%CI=0.90-0.97). The estimate for standard deviation
s is 0.87 (95%CI=0.66-1.03), which implies considerable
variation among batches in prevalence: the odds ratio of
two batches can be as high as 11, e.g., odds ratio 0.9/
(1-0.9) vs 0.45/(1-0.45) for prevalences of 0.90 and 0.45.
Discussion
To establish an HEV antibody assay for pigs, where
HEV Gt3 is the predominant genotype in Europe and
North America, an HEV antibody assay was developed
based on the HEV Gt3 antigen. Since there is increasing
evidence that human autochthonous hepatitis E cases are
linked to swine reservoirs (5,13), HEV antibody testing in
swine is indicated to estimate HEV prevalence. For this
purpose, a validated HEV antibody assay for Europe,
preferably HEV Gt3 based, is needed. Therefore, a re-
combinant expression product of HEV (ORF-2, Gt3,
Subtype 3a) was chosen as antigen. For sensitivity
testing of HEV antibody development in the acute phase
of the infection, a conjugate including HEV-specific IgG
and IgM was used. The effective performance of this for-
mat was tested using a set of serum samples obtained
from experimentally infected pigs.
Validation of HEV antibody assays is hampered by the
fact that a gold standard is not available. To get around this
problem, different approaches have been used including
Western blot and Bayesian analyses (9,14). In this study,
posterior Bayesian statistical inference was used for final
validation and definitive choice of the cutoff value. Through
a combined approach of testing, using swine sera obtained
from experimental infections and from the field, and
comparison of immunoassays using Bayesian evaluation
of the accuracy of the assays, an adequate validation of
the immunoassay could be established.
In the statistical model, it was assumed that there is an
interdependency between assays for true seropositives
and independence for true seronegatives. Without the last
assumption, i.e., allowing for dependence between assays
for true seronegatives as well, quite unrealistic results were
found for the specificity of all three assays. Quite likely, this
is connected to identification problems that influenced the
prevalence structure of batches in the data set. Such
identification problems are not specific to the statistical
approach used in this article, and are potential problems
shared by all methods used for diagnostic test evaluation
in the absence of a gold standard. For true positives,
dependence is likely, since all three immunoassays are
based onmore or less the same principle. Moreover, based
on previous observations, it has been postulated repeat-
edly that it is likely that there is just one single serotype of
mammalian HEV (1). Assumed independence for true
seronegatives was considered reasonable, because in that
case there will not be an immunogenic reaction related to
the selected antigens in the assays.
To better understand HEV transmission in autochtho-
nous HEV infections in humans, HEV surveillance in pigs
is needed. Using an accurately validated, sensitive HEV
antibody assay based on the predominant antigen will
result in more reliable surveillance data. The HEV
antibody assay developed and validated in this study is
suitable for detection of HEV-specific antibodies in swine
reservoirs and can contribute to reliable estimates of HEV
prevalence in swine in different regions.
Supplementary Material
Click here to view [pdf].
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Table 2. Absorbances measured using three different HEV
immunoassays for testing a set of 1100 pig sera obtained at
slaughter.
Immunoassay Average absorbance Range absorbances
CVI Gt3 assay 1.205 0.079-3.313
Axiom 2.054 0.165-4.083
Gt1 assay 0.523 0.047-2.453
See details in Material and Methods.
Table 3. Estimated sensitivity and specificity.
Assay Sensitivity Specificity
CVI Gt3 assay 0.84 (0.81-0.86) 0.89 (0.88-0.90)
Axiom 0.93 (0.90-0.94) 0.89 (0.88-0.90)
Gt1 assay 0.58 (0.55-0.62) 0.94 (0.92-0.96)
95%CI is reported in parentheses.
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